No genetic mutations relating to the occurrence of the solid variant of papillary thyroid carcinoma, including <i>RET</i>/PTC rearrangements and mutations in the <i>BRAF</i> or <i>RAS</i>, were detected by a gene panel test, namely, the OncomineTM Dx Target test. This evidence concerns the gene BRAF and thyroid gland papillary carcinoma.